Getinge Year End Report 2024: Strong order intake and increased sales contributed to sharp improvement in margins
Getinge reported strong performance in Q4 2024, with organic net sales growth of 9.2% and order intake rising 7.4% organically. The company achieved record sales with positive performance across all regions, particularly strong in ventilators. Adjusted EBITA reached SEK 2,143M with a margin of 19.4%, showing significant improvement from Q4 2023.
Notable developments include the successful integration of Paragonix Technologies, acquired in Q3 2024, and FDA 510(k) clearance for the KidneyVault portable renal perfusion system. The company has initiated a strategic process to phase-out the Surgical Perfusion product category to focus on more profitable areas like ECLS and Transplant Care.
For full-year 2024, Getinge reported organic net sales growth of 4.9% and proposed a dividend of SEK 4.60 per share. Looking ahead, the company projects organic sales growth of 2-5% for 2025, supported by stable demand and long-term healthcare needs.
Getinge ha riportato una forte performance nel quarto trimestre del 2024, con una crescita organica delle vendite nette del 9,2% e un aumento del 7,4% negli ordini ricevuti in modo organico. L’azienda ha raggiunto vendite record con prestazioni positive in tutte le regioni, in particolare nei ventilatori. EBITA rettificato ha raggiunto i 2.143 milioni di SEK con un margine del 19,4%, mostrando un significativo miglioramento rispetto al quarto trimestre del 2023.
Tra gli sviluppi notevoli c'è stata l'integrazione riuscita di Paragonix Technologies, acquisita nel terzo trimestre del 2024, e l'approvazione FDA 510(k) per il sistema di perfusione renale portatile KidneyVault. L'azienda ha avviato un processo strategico per eliminare la categoria di prodotto Surgical Perfusion per concentrarsi su aree più redditizie come ECLS e Trapianto.
Per l'intero anno 2024, Getinge ha riportato una crescita organica delle vendite nette del 4,9% e ha proposto un dividendo di 4,60 SEK per azione. Guardando al futuro, l'azienda prevede una crescita delle vendite organiche del 2-5% per il 2025, supportata da una domanda stabile e dai bisogni di assistenza sanitaria a lungo termine.
Getinge reportó un sólido desempeño en el cuarto trimestre de 2024, con un crecimiento de ventas netas orgánicas del 9.2% y un aumento del 7.4% en la captación de pedidos de manera orgánica. La compañía logró ventas récord con un rendimiento positivo en todas las regiones, destacándose especialmente en ventiladores. EBITA ajustado alcanzó los 2,143 millones de SEK con un margen del 19.4%, mostrando una mejora significativa respecto al cuarto trimestre de 2023.
Desarrollos notables incluyen la exitosa integración de Paragonix Technologies, adquirida en el tercer trimestre de 2024, y la aprobación 510(k) de la FDA para el sistema portátil de perfusión renal KidneyVault. La compañía ha iniciado un proceso estratégico para eliminar la categoría de producto de Perfusión Quirúrgica y enfocarse en áreas más rentables como ECLS y Cuidados de Trasplante.
Para todo el año 2024, Getinge reportó un crecimiento de ventas netas orgánicas del 4.9% y propuso un dividendo de 4.60 SEK por acción. De cara al futuro, la compañía proyecta un crecimiento de ventas orgánicas del 2-5% para 2025, apoyado por una demanda estable y necesidades de atención médica a largo plazo.
Getinge는 2024년 4분기 강력한 실적을 보고했으며, 유기적인 순매출 성장률이 9.2%, 주문 접수는 유기적으로 7.4% 증가했습니다. 이 회사는 모든 지역에서 긍정적인 실적을 올리며 특히 인공호흡기에서 높은 성과를 거두었습니다. 조정된 EBITA는 2,143백만 SEK에 이르렀으며, 마진은 19.4%로 2023년 4분기 대비 상당한 개선을 보여주었습니다.
주목할 만한 발전으로는 2024년 3분기에 인수한 Paragonix Technologies의 성공적인 통합과 FDA의 510(k) 승인을 받은 KidneyVault 휴대용 신장 관류 시스템이 있습니다. 이 회사는 Surgical Perfusion 제품 범주를 단계적으로 철수하고 ECLS 및 이식 관리와 같은 더 수익성 있는 분야에 집중하기 위한 전략적 프로세스를 시작했습니다.
2024년 전체에 대해 Getinge는 유기적인 순매출 성장률이 4.9%라고 보고했으며, 주당 4.60 SEK의 배당금을 제안했습니다. 앞으로의 전망으로, 이 회사는 2025년 동안 안정적인 수요와 장기적인 의료 요구를 지원받아 2-5%의 유기적인 판매 성장을 예측하고 있습니다.
Getinge a rapporté une performance solide au quatrième trimestre 2024, avec une croissance organique des ventes nettes de 9,2% et une augmentation organique des commandes de 7,4%. L'entreprise a réalisé des ventes record avec des performances positives dans toutes les régions, particulièrement marqué dans les ventilateurs. EBITA ajusté a atteint 2 143 millions de SEK avec une marge de 19,4%, montrant une amélioration significative par rapport au quatrième trimestre 2023.
Les développements notables incluent l'intégration réussie de Paragonix Technologies, acquise au troisième trimestre 2024, et l'approbation FDA 510(k) pour le système de perfusion rénale portable KidneyVault. L'entreprise a lancé un processus stratégique pour éliminer la catégorie de produits de la perfusion chirurgicale afin de se concentrer sur des domaines plus rentables comme l'ECLS et les soins de transplantation.
Pour l'année complète 2024, Getinge a rapporté une croissance organique des ventes nettes de 4,9% et a proposé un dividende de 4,60 SEK par action. En regardant vers l'avenir, l'entreprise prévoit une croissance des ventes organiques de 2 à 5% pour 2025, soutenue par une demande stable et des besoins de soins de santé à long terme.
Getinge hat im vierten Quartal 2024 eine starke Leistung berichtet, mit einem organischen Umsatzwachstum von 9,2% und einem organischen Anstieg des Auftragseingangs um 7,4%. Das Unternehmen erzielte Rekordverkäufe mit positiven Ergebnissen in allen Regionen, besonders stark bei Beatmungsgeräten. Bereinigtes EBITA erreichte 2.143 Millionen SEK bei einer Marge von 19,4%, was eine signifikante Verbesserung im Vergleich zum vierten Quartal 2023 zeigt.
Zu den bemerkenswerten Entwicklungen gehört die erfolgreiche Integration von Paragonix Technologies, das im dritten Quartal 2024 übernommen wurde, und die FDA 510(k) Genehmigung für das tragbare Nierenperfusion-System KidneyVault. Das Unternehmen hat einen strategischen Prozess eingeleitet, um die Produktkategorie Surgical Perfusion schrittweise abzubauen, um sich auf rentablere Bereiche wie ECLS und Transplantationspflege zu konzentrieren.
Für das gesamte Jahr 2024 berichtete Getinge von einem organischen Umsatzwachstum von 4,9% und schlug eine Dividende von 4,60 SEK pro Aktie vor. Ausblickend prognostiziert das Unternehmen für 2025 ein organisches Umsatzwachstum von 2-5%, unterstützt durch stabile Nachfrage und langfristige Gesundheitsbedürfnisse.
- Record sales with 9.2% organic growth in Q4 2024
- Adjusted EBITA margin improved to 19.4% from 13.3% in Q4 2023
- Strong free cash flow increase to SEK 1,693M from SEK 976M
- FDA 510(k) clearance for KidneyVault system
- Dividend increase proposed to SEK 4.60 from SEK 4.40
- Strategic phase-out of Surgical Perfusion due to unsatisfactory market share
- Geopolitical uncertainty and potential trade barriers noted as risks
Growth was particularly strong in ventilators, where Getinge is benefiting from the consolidation in the market. Furthermore, consumables in ECLS in Acute Care Therapies and Sterile Transfer in Life Science, showed solid performance.
Paragonix Technologies, Inc., which was acquired in Q3 2024, reported impressive growth in the quarter. The KidneyVault portable renal perfusion system, which addresses the largest organ transplant market in terms of volume, received FDA 510(k) clearance. This means that Paragonix now has unique breadth in its product portfolio, which encompasses all major organ categories.
Getinge's focus on structural measures to increase productivity and cost efficiency contributed to the operating margin strengthening significantly compared with Q4 2023.
"The strong cash flow and earnings in the quarter highlight the leverage we have in terms of profitability when we achieve higher sales," says Mattias Perjos.
After the board's review, Getinge has initiated a process with the strategic intention to phase-out the Surgical Perfusion product category, to further strengthen the company's long-term growth and profitability. This would contribute marginally positive to adjusted EBITA from 2025 and gradually increase onwards, thanks to reallocation of resources to attractive areas such as ECLS and Transplant Care. Getinge's market share in Surgical Perfusion is not satisfactory and the market growth is limited.
Despite geopolitical uncertainty and potential trade barriers, demand is expected to be relatively stable, with long-term care needs and hospitals' willingness to invest as continued strong drivers.
"In 2024, we have demonstrated that we are well positioned in prioritized product categories for our customers. This means that we have a positive outlook on 2025 and expect organic sales growth of 2
October – December 2024 in brief
- Net sales increased organically by
9.2% (10.1) and the order intake rose by7.4% organically (-2.4).
• Adjusted gross profit amounted toSEK 5,604 M (4,596) and the margin was50.6% (46.4).
• Adjusted EBITA amounted toSEK 2,143 M (1,318) and the margin was19.4% (13.3).
• Adjusted earnings per share amounted toSEK 5.28 (3.11).
• Free cash flow amounted toSEK 1,693 M (976).
• Initiated process with the intention of discontinuing Surgical Perfusion.
January – December 2024 in brief
• Net sales increased organically by
• Adjusted gross profit amounted to
• Adjusted EBITA amounted to
• Adjusted earnings per share amounted to
• Free cash flow amounted to
• A dividend per share of
Phone Conference
A conference call will be held on January 28, 2025, at 10:00-11:00 a.m. CET hosted by Mattias Perjos, President & CEO, and Agneta Palmér, CFO.
To participate via teleconference, please register via https://conference.financialhearings.com/teleconference/?id=5002483. After registration, you will be provided with telephone numbers and a conference ID to access the conference. You can ask questions verbally via the telephone conference. During the conference call a presentation will be held. To access the presentation through webcast, please use https://getinge.events.inderes.com/q4-report-2024, where a recorded version can be accessed for 3 years.
Contact:
David Kördel, Head of Investor Relations
Phone: +46 (0)10 335 0077
Email: david.kordel@getinge.com
This information is such that Getinge AB is obliged to make public pursuant to the EU Market Abuse Regulation. The
information was submitted for publication, through the agency of the contact person set out above, on January 28, 2025, at 08:00 am CET.
About Getinge
With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions that aim to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. Getinge employs approximately 12,000 people worldwide and the products are sold in more than 135 countries.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Getinge - Report for Q4 and Full year 2024 | |
https://mb.cision.com/Public/942/4090524/8f84d5d0c0bbda10.pdf | Press Release - Getinge Year End Report 2024 |
View original content:https://www.prnewswire.com/news-releases/getinge-year-end-report-2024-strong-order-intake-and-increased-sales-contributed-to-sharp-improvement-in-margins-302362108.html
SOURCE Getinge
FAQ
What was Getinge's (GNGBY) organic sales growth in Q4 2024?
How much did Getinge's (GNGBY) adjusted EBITA margin improve in Q4 2024?
What is Getinge's (GNGBY) projected organic sales growth for 2025?
What dividend per share did Getinge (GNGBY) propose for 2024?
Why is Getinge (GNGBY) phasing out its Surgical Perfusion product category?
